Working with Healthcare Professionals

Our approach

Boehringer Ingelheim has sought to develop innovative new medicines for well over 130 years, in a quest to improve the health and wellbeing of society. These new medicines are the result of decades of research, development and clinical testing. Healthcare professionals play a pivotal role along this development process. As new medicines come to market, with the potential to significantly benefit the health and welfare of patients, Boehringer Ingelheim engages in the education of healthcare professionals to ensure the safe, effective and appropriate use of our medicines.

We also work with healthcare professionals to improve patient care, build shared knowledge and identify future patient needs that can be met through our research and development. This dialogue is critical to ensure that the needs of patients are being best met. We believe that this interaction with healthcare professionals benefits patient care, and enables advances to be made in the therapeutic areas in which the company operates.

We also believe that healthcare professionals who provide independent advice or offer their expertise to develop or deliver appropriate education to relevant audiences should be fairly compensated for their time, services and expertise. Boehringer Ingelheim has for many years supported extensive medical education of Australian and New Zealand healthcare professionals with the aim of improving patient care. Through educational programs accredited by institutions, peer-led meetings, and support of independent scientific meetings, Boehringer Ingelheim is strongly committed to the advancement of patient care.

All of our interactions with healthcare professionals are highly professional, ethical and strictly adhere not only to the company’s high ethical standards, but also to the standards set out in the Medicines Australia Code of Conduct and Medicines New Zealand Code of Practice. We fully understand that the community needs to have confidence in these interactions. The pharmaceutical industry, through Medicines Australia and Medicines New Zealand has been a leader in the healthcare sector in developing and implementing robust codes that governs these relationships to ensure they are ethical and transparent.

Boehringer Ingelheim is committed to listening and evolving to meet community expectations on how we work with healthcare professionals, while providing important medicines that prevent and treat diseases in Australian and New Zealand patients and ensuring quality education both in regard to therapeutic areas and appropriate use of medicines within these areas.

The Transfer of Value Reports

These reports highlight the significant value Boehringer Ingelheim delivers to Australia and New Zealand's healthcare system through the support of professional training and medical education for healthcare professionals. 

Boehringer Ingelheim Australia - Transfer of Value Report

As a member of Medicines Australia, Boehringer Ingelheim has undertaken to be open and transparent when we provide a reportable payment or transfer of value to a healthcare professional.

Reportable payments or transfers of value are:

  • Payments for the provision of services such as giving a lecture, chairing an educational meeting, providing advice as a member of an Advisory Board or as a Consultant; and
  • Airfares, accommodation and/or conference registration fees to attend medical education as part of those services.

Boehringer Ingelheim has prepared the report for publication in accordance with the Medicines Australia Code of Conduct, Edition 19 and Australia’s Privacy legislation. The report identifies healthcare professionals by name where their consent has been provided. 

From 1 October 2016, reporting these payments is mandatory – details will be reported because healthcare professionals should reasonably expect that all reportable payments or transfers of value will be disclosed for each healthcare professional, by name.

From 30 August 2019, this information is now held in a database, administered by Medicines Australia. This database is designed to be searchable as well as downloaded as a CSV file. For further information about the details in the report, or to search the database, please visit www.DisclosureAustralia.com.au

To comply with our privacy obligations, the report may be amended from time to time. The report here contains the most up to date information. Any use or disclosure of the data by a third party is the responsibility of that third party, who must comply with the Australian Privacy Act 1988.

For further information about the details in the report, please go to medicinesaustralia.com.au

Learn more about how we work with Health Consumer Organisations 

Learn more about Clinical Research in Australia

 

Boehringer Ingelheim New Zealand - Transfer of Value Report

As a member of Medicines New Zealand, Boehringer Ingelheim has undertaken to be open and transparent when we provide a reportable payment or transfer of value to a healthcare professional.

Reportable payments or transfers of value are:

  • Payments for the provision of services such as giving a lecture, chairing an educational meeting, providing advice as a member of an Advisory Board or as a Consultant; and
  • Airfares, accommodation and/or conference registration fees to attend medical education as part of those services.

Boehringer Ingelheim has prepared the report for publication in accordance with the Medicines New Zealand Guidelines for Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and New Zealand’s Privacy legislation. The report identifies healthcare professionals by name where their consent has been provided. Where consent has not been provided the information is reported in aggregate.

From 1 January 2021, reporting these payments is voluntary– details will be reported because healthcare professionals should reasonably expect that all reportable payments or transfers of value will be disclosed for each healthcare professional, by name. The report is available for at least three years from the date of publication.

To comply with our privacy obligations, the report may be amended from time to time. The report here contains the most up to date information. Any use or disclosure of the data by a third party is the responsibility of that third party, who must comply with the New Zealand’s Privacy Act 2020.

For further information about the details in the report, please go to Transparency Guidelines - Medicines (medicinesnz.co.nz)

 

Reporting Period Report File
2021
January 1 - December 31

Access the pdf report here